1. Prieto L.I., Graves S.I., Baker D.J. Insights from In Vivo Studies of Cellular Senescence. Cells. 2020;9(4):954. DOI: 10.3390/cells9040954.
2. Libertini G. Non-programmed versus programmed aging paradigm. Curr Aging Sci. 2015;8(1):56–68. DOI: 10.2174/1874609808666150422111623.
3. Libertini G., Ferrara N. Aging of perennial cells and organ parts according to the programmed aging paradigm. Age (Dordr). 2016;38(2):35. DOI: 10.1007/s11357-016-9895-0.
4. Perona R., Iarriccio L., Pintado-Berninches L. et al. Molecular diagnosis and precission therapeutic approaches for telomere biology disorders. Telomeres: INTECH. 2016;77–117. DOI: 10.5772/65353.
5. Sanders J.L., Newman A.B. Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? Epidemiol. Rev. 2013;35:112–131. DOI: 10.1093/epirev/mxs008.
6. Bernadotte A., Mikhelson V.M., Spivak I.M. Markers of cellular senescence. Telomere shortening as a marker of cellular senescence. Aging (Albany NY). 2016;8(1):3–11. DOI: 10.18632/aging.100871.
7. Lu W., Zhang Y., Liu D. et al. Telomeres-structure, function, and regulation. Exp Cell Res. 2013;319(2):133–141. DOI: 10.1016/j.yexcr.2012.09.005.
8. López-Otín C., Blasco M.A., Partridge L. et al. The hallmarks of aging. Cell. 2013;153(6):1194–1217. DOI: 10.1016/j.cell.2013.05.039.
9. Martínez P., Blasco M.A. Telomere-driven diseases and telomere-targeting therapies. J Cell Biol. 2017;216(4):875–887. DOI: 10.1083/jcb.201610111.
10. Zhdanova N.S., Rubtsov N.B. Telomere Recombination in Normal Mammalian Cells. Genetika. 2016;52(1):14–23. DOI: 10.7868/S0016675816010148.
11. Bodnar A.G., Ouellette M., Frolkis M. et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279(5349):349–352. DOI: 10.1126/science.279.5349.349.
12. Counter C.M., Meyerson M., Eaton E.N. et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998;16(9):1217–1222. DOI: 10.1038/sj.onc.1201882.
13. Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol. 1998;8(5):279–282. DOI: 10.1016/s0960-9822 (98) 70109-5.
14. De Punder K., Heim C., Wadhwa P.D., Entringer S. Stress and immunosenescence: The role of telomerase. Psychoneuroendocrinology. 2019;101:87–100. DOI: 10.1016/j.psyneuen.2018.10.019.
15. Dey A., Chakrabarti K. Current Perspectives of Telomerase Structure and Function in Eukaryotes with Emerging Views on Telomerase in Human Parasites. Int J Mol Sci. 2018;19(2):333. DOI: 10.3390/ijms19020333.
16. Tchkonia T., Zhu Y., van Deursen J. et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123(3):966–972. DOI: 10.1172/JCI64098.
17. Shay J.W.. Role of Telomeres and Telomerase in Aging and Cancer. Cancer Discov. 2016;6(6):584–593. DOI: 10.1158/2159-8290.CD-16-0062.
18. Lee S.H., Lee J.H., Lee H.Y., Min K.J. Sirtuin signaling in cellular senescence and aging. BMB Rep. 2019;52(1):24–34. DOI: 10.5483/BMBRep.2019.52.1.290.
19. Cardus A., Uryga A.K., Walters G., Erusalimsky J.D. SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence. Cardiovasc Res. 2013;97(3):571–579. DOI: 10.1093/cvr/cvs352.
20. Grabowska W., Sikora E., Bielak-Zmijewska A. Sirtuins, a promising target in slowing down the ageing process. Biogerontology. 2017;18(4):447–476. DOI: 10.1007/s10522-017-9685-9.
21. Hisayuki Amano H., Sahin E. Telomeres and sirtuins: at the end we meet again. Mol Cell Oncol. 2019;6(5): e1632613. DOI: 10.1080/23723556.2019.1632613.
22. Amano H., Chaudhury A., Rodriguez-Aguayo C. et al. Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease. Cell Metab. 2019;29(6):1274–1290. DOI: 10.1016/j.cmet.2019.03.001.
23. Lambert N.G., ElShelmani H., Singh M.K. et al. Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res. 2016;54:64–102. DOI: 10.1016/j.preteyeres.2016.04.003.
24. Curcio C.A. Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies. Invest Ophthalmol Vis Sci. 2018;59(4):160–181. DOI: 10.1167/iovs.18-24882.
25. Weng X., Zhang H., Kan M. et al. Leukocyte telomere length is associated with advanced age-related macular degeneration in the Han Chinese population. Exp Gerontol. 2015;69:36–40. DOI: 10.1016/j.exger.2015.06.004.
26. Immonen I., Seitsonen S., Saionmaa O., Fyhrquist F. Leucocyte telomere length in age-related macular degeneration. Acta Ophthalmol. 2013;91(5):453–456. DOI: 10.1111/j.1755-3768.2012.02427.x.
27. Bär C., Blasco M.A. Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases. F1000Res. 2016;5:89. DOI: 10.12688/f1000research.7020.1.
28. Varela E., Muñoz-Lorente M.A., Tejera A.M. et al. Generation of mice with longer and better preserved telomeres in the absence of genetic manipulations. Nat Commun. 2016;7:11739. DOI: 10.1038/ncomms11739.
29. Ramunas J., Yakubov E., Brady J.J. et al. Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells. FASEB J. 2015;29(5):1930–1939. DOI: 10.1096/fj.14-259531.
30. Harley C.B., Liu W., Flom P.L., Raffaele J.M. A natural product telomerase activator as part of a health maintenance program: metabolic and cardiovascular response. Rejuvenation Res. 2013;16(5):386–395. DOI: 10.1089/rej.2013.1430.
31. Dow C.T., Harley C.B. Evaluation of an oral telomerase activator for early age-related macular degeneration — a pilot study. Clin Ophthalmol. 2016;10:243–249. DOI: 10.2147/OPTH.S100042.
32. Dong X.X., Hui Z.J., Xiang W.X. et al. Ginkgo biloba extract reduces endothelial progenitor-cell senescence through augmentation of telomerase activity. J Cardiovasc Pharmacol. 2007;49(2):111–115. DOI: 10.1097/FJC.0b013e31802ef519.
33. Rastmanesh R. Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity. Med Hypotheses. 2011;76(1):79–85. DOI: 10.1016/j.mehy.2010.08.036.
34. Boccardi V., Esposito A., Rizzo M.R. et al. Mediterranean diet, telomere maintenance and health status among elderly. PLoS One. 2013;8(4): e62781. DOI: 10.1371/journal.pone.0062781.
35. Crous-Bou M., Fung T.T., Prescott J. et al. Mediterranean diet and telomere length in Nurses’ Health Study: population based cohort study. BMJ. 2014;349: g6674. DOI: 10.1136/bmj.g6674.
36. Жумагул М.Ж., Кыдырбаева А.К., Танеева Г.Т. и др. Влияние эпигенетических факторов на укорочение теломер. Вестник КазНМУ. 2018;1:457–459. [Zhumagul M.Z., Kydyrbaeva A.K., Taneyeva G.T. et al. Influence of epigenetic factors on the short-termination. Vestnik KazNMU. 2018;1:457–459 (in Russ.)]. DOI: 10.24412/FhbsrgA3j8I.
37. Nashine S., Nesburn A.B., Kuppermann B.D., Kenney M.C. Role of Resveratrol in Transmitochondrial AMD RPE Cells. Nutrients. 2020;12(1):159. DOI: 10.3390/nu12010159.
38. Yang Y., Wu Z.Z., Cheng Y.L. et al. Resveratrol protects against oxidative damage of retinal pigment epithelium cells by modulating SOD/MDA activity and activating Bcl-2 expression. Eur Rev Med Pharmacol Sci. 2019;23(1):378–388. DOI: 10.26355/eurrev_201901_16786.